International Conference on Hematology and Oncology June 29- July 1, 2017 Bangkok, Thailand

Lixin Rui trained as an oncologist in China and completed his PhD at the Australian National University. In 2006, he received a CJ Martin Postdoctoral Fellowship and started lymphoma research in Louis Staudt's lab at the National Cancer Institute. In December 2012, Dr. Rui joined the Division of Hematology/Oncology as an Assistant Professor in the Department of Medicine at the University of Wisconsin-Madison. Dr. Rui's research in his lab focuses on lymphoma biology, with an emphasis on JAK-STAT signaling in lymphomagenesis.

Hematology/Oncology

Amal zaghloul has completed her medical doctorate in clinical pathology with specialty in hematology at the age of 34 years from faculty of medicine Ain shams University Cairo Egypt. She is a professor of clinical pathology (hematology) at faculty of medicine Umm Alqura University (Saudi Arabia) and at faculty of medicine Ain Shams university (Cairo Egypt). She has participated in both theoretical and practical teaching of Hematology. Also, supervising research works of under and postgraduate students. She has experience in the flow cytometry, immunohistochemistry and ELISA . She has published more than 25 papers in reputed journals

Hematology

After completion of his postdoctoral training at University of Texas MD Anderson Cancer Center, Prof. Gautam Sethi joined Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore in 2008 as an Assistant Professor and was promoted to Associate Professor in 2015. The focus of his research over the past few years has been to elucidate the mechanism (s) of activation of oncogenic transcription factors such as NF-kB/STAT3 by carcinogens and inflammatory agents and the identification of novel inhibitors of these proteins for prevention of and therapy for cancer. The findings of his research work have so far resulted in more than one hundred and fifty scientific publications in high impact factor peer reviewed journals and several international awards. He currently serves as an Academic Editor for PLOS, editorial board member of Scientific Reports, and ad-hoc reviewer for several other international journals.

Hematology and Oncology

Professor Engert studied and promoted human medicine at the Hannover Medical School and began his clinical training at the Medical University Clinic in Cologne.From 1996 to 2000 he worked as a staff superintendent and has been the deputy director of the hospital since 2000. In 2001, he was appointed a university professor of the Faculty of Medicine.

The focus of research is the improvement of the treatment results for patients with malignant lymphomas, new targeted therapies based on monoclonal antibodies or antibody fragments are further developed in order to destroy malignant cells in a targeted manner

Director, Institute of Hematology and Transfusiology, Tbilisi, Georgia from 2007. Vice President of Georgian Association of Hematology and Transfusiology, Tbilisi member of EHA. Doctor Hematologist/Transfusioilogist, Institute of Hematology and Transfusiology, Tbilisi, Georgia Associated Professor, Hematological Department, Georgian State Medical University, Tbilisi, Georgia

Hematology & Transfusiology

Lixin Rui trained as an oncologist in China and completed his PhD at the Australian National University. In 2006, he received a CJ Martin Postdoctoral Fellowship and started lymphoma research in Louis Staudt's lab at the National Cancer Institute. In December 2012, Dr. Rui joined the Division of Hematology/Oncology as an Assistant Professor in the Department of Medicine at the University of Wisconsin-Madison. Dr. Rui's research in his lab focuses on lymphoma biology, with an emphasis on JAK-STAT signaling in lymphomagenesis.

Hematology/Oncology and Lymphoma